Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease (ANOCA-CMD)
1 other identifier
observational
100
1 country
1
Brief Summary
The goal of this observational study is to explore the incidence and effect on prognosis of coronary microvascular dysfunction in patients present of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) \>0.80.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2023
CompletedFirst Submitted
Initial submission to the registry
July 10, 2024
CompletedFirst Posted
Study publicly available on registry
July 16, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedJuly 16, 2024
July 1, 2024
1.5 years
July 10, 2024
July 10, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
MACE in 12 months
major adverse cardiovascular events 12 months, including cardiac death, myocardial infarction, and readmission for angina.
12 months
Eligibility Criteria
Patients present of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) \>0.80
You may qualify if:
- presence of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) \>0.80
You may not qualify if:
- acute myocardial infarction
- significant valvular heart disease
- advanced chronic kidney disease
- patients with significant epicardial coronary artery stenosis (\>70% in major vessels by diagnostic coronary angiography) needing percutaneous coronary intervention
- patients unable to provide written informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of Cardiology Department
Study Record Dates
First Submitted
July 10, 2024
First Posted
July 16, 2024
Study Start
July 1, 2023
Primary Completion
December 31, 2024
Study Completion
December 31, 2025
Last Updated
July 16, 2024
Record last verified: 2024-07
Data Sharing
- IPD Sharing
- Will not share